Abdulhakeem Olarewaju Sulyman

Dr. Abdulhakeem Olarewaju Sulyman


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Global Health Science
Verified
Journal Article
Open access
PDF file
ARAbdulrahman Olamilekan Raji
Abdulrahman Olamilekan Raji
HLHABEEB LAWAL
HABEEB LAWAL
ZSZainab Ajoke Suleiman
Zainab Ajoke Suleiman
AOAisha Eniola Olayiwola
Aisha Eniola Olayiwola
WMWahab Muiz
Wahab Muiz
ASAbdulhakeem Olarewaju Sulyman
Abdulhakeem Olarewaju Sulyman
Raji AO, et al. J Glob Health Sci. 2025 Dec;8:e2. https://doi.org/10.35500/jghs.2026.8.e2

13 January 2018 in Iranian Journal of Science and Technology, Transactions A: Science
Verified
Journal Article
Closed access
PDF file
JAJubril Olayinka Akolade
Jubril Olayinka Akolade
ANAsiat Na’aLlah
Asiat Na’aLlah
ASAbdulhakeem Olarewaju Sulyman
Abdulhakeem Olarewaju Sulyman
AAAzeemat Titilola Abdulazeez
Azeemat Titilola Abdulazeez
AAAsiata Opeyemi Atoti
Asiata Opeyemi Atoti
MIMardiya Bawa Isiaku
Mardiya Bawa Isiaku

28 January 2025 in Scientific African
Verified
Journal Article
Open access
ASAbdulhakeem Olarewaju Sulyman
Abdulhakeem Olarewaju Sulyman
OAOlawale Moshood Aliyu
Olawale Moshood Aliyu
EAEmmanuel Oladipo Ajani
Emmanuel Oladipo Ajani
YAYusuf Folohunsho Abdulkareem
Yusuf Folohunsho Abdulkareem
IAIsaac Ade Afe
Isaac Ade Afe
KNKuben Naidoo
Kuben Naidoo

20 September 2023 in BioTech
Verified
Journal Article
Open access
PDF file
ASAbdulhakeem Olarewaju Sulyman
Abdulhakeem Olarewaju Sulyman
JFJessie Fulcher
Jessie Fulcher
SCSamuel Crossley
Samuel Crossley
AFAmos Fatokun
Amos Fatokun
FOFemi Olorunniji
Femi Olorunniji
Low-molecular-weight protein tyrosine phosphatases (LMW-PTPs) are involved in promoting the intracellular survival of Mycobacterium tuberculosis (Mtb), the causative organism of tuberculosis. These PTPs directly alter host signalling pathways to evade the hostile environment of macrophages and avoid host clearance. Among these, protein tyrosine phosphatase A (Mt-PTPa) is implicated in phagosome acidification failure, thereby inhibiting phagosome maturation to promote Mycobacterium tuberculosis (Mtb) survival. In this study, we explored Mt-PTPa as a potential drug target for treating Mtb. We started by screening a library of 502 pure natural compounds against the activities of Mt-PTPa in vitro, with a threshold of 50% inhibition of activity via a <500 µM concentration of the candidate drugs. The initial screen identified epigallocatechin, myricetin, rosmarinic acid, and shikonin as hits. Among these, the naphthoquinone, shikonin (5, 8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-3-pentenyl]-1,4-naphthoquinone), showed the strongest inhibition (IC50 33 µM). Further tests showed that juglone (5-hydroxy-1,4-naphthalenedione), another naphthoquinone, displayed similar potent inhibition of Mt-PTPa to shikonin. Kinetic analysis of the inhibition patterns suggests a non-competitive inhibition mechanism for both compounds, with inhibitor constants (Ki) of 8.5 µM and 12.5 µM for shikonin and juglone, respectively. Our findings are consistent with earlier studies suggesting that Mt-PTPa is susceptible to specific allosteric modulation via a non-competitive or mixed inhibition mechanism.

1 January 2023 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ASAbdulhakeem Olarewaju Sulyman
Abdulhakeem Olarewaju Sulyman
OAOluwapelumi Oluwaseun Aje
Oluwapelumi Oluwaseun Aje
EAEmmanuel Oladipo Ajani
Emmanuel Oladipo Ajani
RARukayat Abiola Abdulsalam
Rukayat Abiola Abdulsalam
Fatai Oladunni BalogunFatai Oladunni Balogun
Fatai Oladunni Balogun
SSSaheed Sabiu
Saheed Sabiu
Malaria is a devastating disease, and its management is only achieved through chemotherapy. However, resistance to available medication is still a challenge; therefore, there is an urgent need for the discovery and development of therapeutics with a novel mechanism of action to counter the resistance scourge consistent with the currently available antimalarials. Recently, plasmepsin V was validated as a therapeutic target for the treatment of malaria. The pepsin‐like aspartic protease anchored in the endoplasmic reticulum is responsible for the trafficking of parasite‐derived proteins to the erythrocytic surface of the host cells. In this study, a small library of compounds was preliminarily screened in vitro to identify novel modulators of Plasmodium falciparum plasmepsin V (PfPMV). The results obtained revealed kaempferol, quercetin, and shikonin as possible PfPMV inhibitors, and these compounds were subsequently probed for their inhibitory potentials using in vitro and in silico methods. Kaempferol and shikonin noncompetitively and competitively inhibited the specific activity of PfPMV in vitro with IC50 values of 22.4 and 43.34 μM, respectively, relative to 62.6 μM obtained for pepstatin, a known aspartic protease inhibitor. Further insight into the structure‐activity relationship of the compounds through a 100 ns molecular dynamic (MD) simulation showed that all the test compounds had a significant affinity for PfPMV, with quercetin (‐36.56 kcal/mol) being the most prominent metabolite displaying comparable activity to pepstatin (‐35.72 kcal/mol). This observation was further supported by the compactness and flexibility of the resulting complexes where the compounds do not compromise the structural integrity of PfPMV but rather stabilized and interacted with the active site amino acid residues critical to PfPMV modulation. Considering the findings in this study, quercetin, kaempferol, and shikonin could be proposed as novel aspartic protease inhibitors worthy of further investigation in the treatment of malaria.

Verified
Journal Article
Open access
PDF file
ASAbdulhakeem Olarewaju Sulyman
Abdulhakeem Olarewaju Sulyman
TYTafa Ndagi Akanbi Yusuf
Tafa Ndagi Akanbi Yusuf
JAJamiu Olaseni Aribisala
Jamiu Olaseni Aribisala
KIKamaldeen Sanni Ibrahim
Kamaldeen Sanni Ibrahim
EAEmmanuel Oladipo Ajani
Emmanuel Oladipo Ajani
KSKarishma Singh
Karishma Singh
Cancer, a group of diseases characterized by uncontrollable cell proliferation and metastasis, remains a global health challenge. This study investigates quercetin, a natural compound found in many fruits and vegetables, for its potential to inhibit the phosphomonoesterase activity of protein tyrosine phosphatase nonreceptor type 22 (PTPN22), a key immune response regulator implicated in cancer and autoimmune diseases. We started by screening seven (7) natural compounds against the activities of PTPN22 in vitro. The initial screening identified quercetin with the highest percentage inhibition (81%) among the screened compounds when compared with ursolic acid that has 84%. After the identification of quercetin, we proceeded by investigating the effect of increasing concentrations of the compound on the activity of PTPN22. In vitro studies showed that quercetin inhibited PTPN22 with an IC50 of 29.59 μM, outperforming the reference standard ursolic acid, which had an IC50 of 37.19 μM. Kinetic studies indicated a non-competitive inhibition by quercetin with a Ki of 550 μM. In silico analysis supported these findings, showing quercetin’s better binding affinity (ΔGbind −24.56 kcal/mol) compared to ursolic acid, attributed to its higher reactivity and electron interaction capabilities at PTPN22′s binding pocket. Both quercetin and ursolic acid improved the structural stability of PTPN22 during simulations. These results suggest quercetin’s potential as an anticancer agent, meriting further research. However, in vivo studies and clinical trials are necessary to fully assess its efficacy and safety, and to better understand its mechanisms of action.